Skip to content
DraconiticResearch
Search Sources API
197,761 studies31 sourcesUpdated 30 min ago
Peer-reviewedCC BY-NC-NDCirculation Journal

Bridging Experience and New Frontiers in Left Ventricular Assist Device Therapy in Japan ― Insights From the J-MACS Report ―

  • Toru Hashimoto
  • Kohtaro Abe
Read full textPDFDOICite

Abstract

tality rates >40%. 1 Intravenous inotropes and durable left ventricular assist devices (LVAD) as bridge-to-transplan-D espite advancements in both medical treatment and interventional therapeutics for heart failure (HF), many patients still progress into an advanced phase.The prognosis of medically treated patients with advanced HF remains poor, with 1-year mor-Article p ????The opinions expressed in this article are not necessarily those of the editors or of the Japanese Circulation Society.

Related

  1. Single-center experience with Romiplostim N01 for the management of severe persistent cancer therapy-induced thrombocytopenia in lung cancer : Insights and outcomes
    Changjian Wang, Chuangyan Wu, Geng Wang +6
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Bridging the airway microbiome and targeted therapy in bronchiectasis: multi-omics insights, endotypes and emerging therapies
    Christina S. Thornton, Laura Schaupp, Michael M. Tunney +1
    The European Respiratory JournalPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
  3. Current role of boron neutron capture therapy in head and neck cancer: insights from 4 years of clinical experience.
    Satoshi Takeno, Yuki Yoshino, Teruhito Aihara +13
    Clinical and translational radiation oncologyPeer-reviewedCC BYFull textMedical imaging & radiologyEurope PMC
  4. Cardiorenal Syndrome: From Hemodynamic and Humoral Pathophysiology to New Frontiers in Modulation and Enabling Therapy—Part 2
    Alfredo Mauriello, Valeria Cetoretta, Carmen Del Giudice +7
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Cardiorenal Syndrome: From Hemodynamic and Humoral Pathophysiology to New Frontiers in Modulation and Enabling Therapy—Part 1
    Alfredo Mauriello, Valeria Cetoretta, Carmen Del Giudice +7
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{hashimoto2026bridging,
  title = {{Bridging Experience and New Frontiers in Left Ventricular Assist Device Therapy in Japan ― Insights From the J-MACS Report ―}},
  author = {Toru Hashimoto and Kohtaro Abe},
  journal = {Circulation Journal},
  year = {2026},
  month = oct,
  doi = {10.1253/circj.cj-26-0991},
  url = {https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0991/_article},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Bridging Experience and New Frontiers in Left Ventricular Assist Device Therapy in Japan ― Insights From the J-MACS Report ―
AU  - Toru Hashimoto
AU  - Kohtaro Abe
PY  - 2026
DA  - 2026/10/23
JO  - Circulation Journal
DO  - 10.1253/circj.cj-26-0991
UR  - https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0991/_article
AB  - tality rates >40%. 1 Intravenous inotropes and durable left ventricular assist devices (LVAD) as bridge-to-transplan-D espite advancements in both medical treatment and interventional therapeutics for heart failure (HF), many patients still progress into an advanced phase.The prognosis of medically treated patients with advanced HF remains poor, with 1-year mor-Article p ????The opinions expressed in this article are not necessarily those of the editors or of the Japanese Circulation Society.
SN  - 1347-4820
SN  - 1346-9843
ER  -